If you have been reading about reversed-phase HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Includes the 39-residue backbone and the attached fatty diacid |
| Molecular weight | Approximately 4813 Da | Average mass; the monoisotopic value is slightly lower |
| Receptor targets | GIP receptor and GLP-1 receptor | Dual engagement defines the pharmacological class |
| Backbone length | 39 amino acids | Sequence modified from native glucose-dependent insulinotropic polypeptide |
| Albumin interaction | Reversible, mediated by the fatty diacid | Slows renal clearance and lengthens circulation time |
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
== Uses in cell biology == Verapamil inhibits the ATP-binding cassette (ABC) transporter family of proteins found in stem cells and has been used to study cancer stem cells (CSC) within head and neck squamous cell carcinomas. Verapamil is also used in cell biology as an inhibitor of drug efflux pump proteins such as P-glycoprotein and other ABC transporter proteins. This is useful, as many tumor cell lines overexpress drug efflux pumps, limiting the effectiveness of cytotoxic drugs or fluorescent tags. It is also used in fluorescent cell sorting for DNA content, as it blocks efflux of a variety of DNA-binding fluorophores such as Hoechst 33342. Radioactively labelled verapamil and positron emission tomography can be used with to measure P-glycoprotein function.
Letrozole and anastrozole are aromatase inhibitors which have been shown to be superior to tamoxifen for the first-line treatment of breast cancer in postmenopausal women. Exemestane is an irreversible "aromatase inactivator" which is superior to megestrol acetate for treatment of tamoxifen-refractory metastatic breast cancer, and does not appear to have the osteoporosis-promoting side effects of other drugs in this class. Aminoglutethimide inhibits both aromatase and other enzymes critical for steroid hormone synthesis in the adrenal glands. It was formerly used for breast cancer treatment, but has since been replaced by more selective aromatase inhibitors. It can also be used for the treatment of hyperadrenocortical syndromes, such as Cushing's syndrome and hyperaldosteronism in adrenocortical carcinoma.
Herbie Hancock – electric piano (Rhodes, clavinet), synthesizer/FX Melvin "Wah Wah" Ragin – guitar Ray Parker Jr. – guitar Paul Jackson – electric bass James Levi – drums Kenneth Nash – percussion Bennie Maupin – tenor & soprano saxophones, lyricon
"A quick and simple introduction to Drosophila melanogaster". Drosophila Virtual Library. "Drosophila Genomics Resource Center" – collects, maintains and distributes Drosophila DNA clones and cell lines. "Bloomington Drosophila Stock Center" – collects, maintains and distributes Drosophila melanogaster strains for research "FlyBase—A Database of Drosophila Genes & Genomes". Archived from the original on November 3, 2018. Retrieved January 28, 2011. "NCBI Map Viewer – Drosophila melanogaster". Archived from the original on June 5, 2003. "Drosophila Virtual Library". "The Berkeley Drosophila Genome Project". "FlyMove". – video resources for Drosophila development "Drosophila Nomenclature—naming of genes". Archived from the original on October 8, 2011. View the Fruitfly genome on Ensembl View the dm6 genome assembly in the UCSC Genome Browser Manchester Fly Facility – for the public Archived 2015-05-13 at the Wayback Machine from the University of Manchester The droso4schools website with school-relevant resources about Drosophila Part 1 of the "Small fly: BIG impact" educational videos explaining the history and importance of the model organism Drosophila. Part 2 of the "Small fly: BIG impact" educational videos explaining how research is carried out in Drosophila. "Inside the Fly Lab"—broadcast by WGBH and PBS, in the program series Curious, January 2008. "How a Fly Detects Poison" Deprecated link archived 2013-01-13 at archive.today—WhyFiles.org article describes how the fruit fly tastes a larva-killing chemical in food.
tRNAs with modified anticodons and/or acceptor stems can be used to modify the genetic code. Scientists have successfully repurposed codons (sense and stop) to accept amino acids (natural and novel), for both initiation (see: start codon) and elongation. In 1990, tRNAfMet2CUA (modified from the tRNAfMet2CAU gene metY) was inserted into E. coli, causing it to initiate protein synthesis at the UAG stop codon, as long as it is preceded by a strong Shine-Dalgarno sequence. At initiation it not only inserts the traditional formylmethionine, but also formylglutamine, as glutamyl-tRNA synthase also recognizes the new tRNA. The experiment was repeated in 1993, now with an elongator tRNA modified to be recognized by the methionyl-tRNA formyltransferase. A similar result was obtained in Mycobacterium. Later experiments showed that the new tRNA was orthogonal to the regular AUG start codon showing no detectable off-target translation initiation events in a genomically recoded E. coli strain.
Sources: en.wikipedia.org
Layne Thomas Staley (; born Layne Rutherford Staley; August 22, 1967 – April 5, 2002) was an American singer-songwriter. He was the original lead vocalist of Alice in Chains, which rose to international fame in the early 1990s as part of Seattle's grunge movement. He was known for his distinctive vocal style as well as his harmonizing with bandmate Jerry Cantrell. Before his success with Alice in Chains, Staley was also a member of the glam metal bands Sleze and Alice N' Chains. He was also a part of the supergroups Mad Season and Class of '99. "Man in the Box", the second single from Alice in Chains' debut album, Facelift (1990), garnered Staley critical recognition for his vocal style. Alice in Chains' EP Jar of Flies (1994), debuted at number one on the Billboard 200, making it Alice in Chains' first record—and the first-ever EP—to top the chart. However, Staley's deteriorating condition due to heroin abuse led him to enter a rehabilitation clinic. He began to work on a side project with several Seattle musicians, Mike McCready of Pearl Jam, Barrett Martin of Screaming Trees, and John Baker Saunders of the Walkabouts, which came to be Mad Season, while Alice in Chains went into hiatus. During Alice in Chains' hiatus, reports of Staley's drug addiction began to gain widespread circulation in fan and media communities, in part due to changes in his physical condition brought on by prolonged heroin abuse. On April 10, 1996, the band returned with a performance on MTV Unplugged in New York; it was Alice in Chains' first concert in two-and-a-half years.
== Sustainable development == The Sustainable Development Index (SDI) measures the ecological efficiency of human development. Its impetus was a reaction to the UN's Human Development Index (HDI) which measures various indicators of development, but does not assess the sustainability of those underlying indicators. Countries with high human development and low ecological impact rise to the top of the SDI. Countries with low human development, and countries with high human development but high ecological impact, fall to the bottom of the SDI. The latest iteration of the index (2020) uses data from 2015, the most recent year for which data is available. In this ranking of 163 nations, Thailand ranked 44. Other ASEAN nations were ranked: Philippines, 26; Indonesia, 30; Vietnam, 42; Laos, 66; Cambodia, 77; Myanmar, 79; Malaysia, 109; Brunei, 139; and Singapore, lowest of all nations at 163.
István Weszprémi Award, University Medical School of Debrecen (1977) Fogarty International Research Fellowship, NIH (1989–1990) Distinguished Scientist Award, Japanese Society for the Promotion of Science (1992) Pándy and Jendrassik Awards, Hungarian Society of Laboratory Medicine (1992, 2000) Széchenyi Professorial Scholarship (1997–2000) Medal for Hungarian Higher Education (1998) Medal of the Hungarian Public Health Scientific Society (2000, 2006) Albert Szent‑Györgyi Medal (2001) Hatvani Award of the City of Debrecen (2005) Semmelweis Award (2006) Öveges Professorial Scholarship (2006) Endre Hőgyes Award (2007) Leó Szilárd Professorial Scholarship (2009) Pro Auditoribus Universitatis Debreceniensis Award (2010) Pro Urbe Award of the City of Debrecen (2011) Krompecher Award, University of Debrecen (2013) Budapest Award (2013) WHO Regional Director’s Award (2019, 2023) H.R. Leavell Award, World Federation of Public Health Associations (2020) Ádám Szendei Award (2020) Officer’s Cross of the Order of Merit of Hungary (2022)
Despite this toxicity, consumption of heavy water under normal circumstances does not pose a health threat to humans. It is estimated that a 70 kg (154 lb) person might drink 4.8 litres (1.3 US gal) of heavy water without serious consequences. Small doses of heavy water (a few grams in humans, containing an amount of deuterium comparable to that normally present in the body) are routinely used as harmless metabolic tracers in humans and animals.
=== Indolin derivatives === Indolin derivatives on the market are Sunitinib and Intedanib. Two indol derivatives that target the VEGF pathway, semaxanib and sunitinib, have been developed. The former is potent but was inefficient in clinical trials and the latter has many side effects. There is need for a drug with pharmacological effects similar to semaxanib and sunitinib, but it needs to be less toxic. MPEG3-9-semaxanib is semaxanib with an additional water-soluble, non-peptidic oligomer attached to it via a spacer moiety. MPEG3-9-semaxanib derivatives are 10 times more active against VEGFR-2 than sunitinib. Compounds with sunitinib heterocyclic moiety but different amide side chains inhibit VEGFR-1 and VEGFR-2 and regulate disorders. Another compound with sunitinib heterocyclic moiety and a pyrrole side chain has very good VEGFR-2 potency, with an IC50 of 65 nM. N-indol-1-amide compound is a possible anti-tumor drug in combination with other anticancer treatment and has an IC50 value of 31 nM. There are many indol derivatives with different side chains that target multiple kinases and take part in several pathways in tumor development. Intedanib is a multiple tyrosine kinase inhibitor and is the first drug to treat idiopathic pulmonary fibrosis. Indol derivatives with 1-NH of 2-indolinone motif that is an H-bond donor, and 2-carbonyl oxygen that acts as an H-bond acceptor, bind with Glu915 and Cys917, respectively. These compounds have basic amine side chains or nitrogen heterocycles and provide ideal solubility and pharmacokinetics.
Sources: en.wikipedia.org
-value is much higher. Neutral 187Re does undergo β− decay, with half-life 4.12×1010 years, but Bosch et al., also at Darmstadt, observed that for fully ionized 187Re75+ this is shortened to only 32.9 years. The increase in Q-value of beta decay typically means that additional decay paths to some excited states of the daughter nucleus become energetically allowed. This is exactly what happens in the case of 187Re: in addition to the large increase in decay energy, 187Re75+ is energetically allowed to undergo β− decay to the first-excited state in 187Os75+, a process energetically disallowed for natural 187Re. Similarly, neutral 241Pu undergoes β− decay with a half-life of 14.3 years, but in its fully ionized state the beta-decay half-life of 241Pu94+ decreases to 4.2 days. For comparison, the variation of decay rates of other nuclear processes due to chemical environment is less than 1%. Theoretical examples of nuclides in this category with
=== Biosynthesis === In plants cellulose is synthesized at the plasma membrane by rosette terminal complexes (RTCs). The RTCs are hexameric protein structures, approximately 25 nm in diameter, that contain the cellulose synthase enzymes that synthesize the individual cellulose chains. Each RTC floats in the cell's plasma membrane and "spins" a microfibril into the cell wall. RTCs contain at least three different cellulose synthases, encoded by CesA (Ces is short for "cellulose synthase") genes, in an unknown stoichiometry. Separate sets of CesA genes are involved in primary and secondary cell wall biosynthesis. There are known to be about seven subfamilies in the plant CesA superfamily, some of which include the more cryptic, tentatively-named Csl (cellulose synthase-like) enzymes. These cellulose syntheses use UDP-glucose to form the β(1→4)-linked cellulose. Bacterial cellulose is produced using the same family of proteins, although the gene is called BcsA for "bacterial cellulose synthase" or CelA for "cellulose" in many instances. In fact, plants acquired CesA from the endosymbiosis event that produced the chloroplast. All cellulose synthases known belongs to glycosyltransferase family 2 (GT2). Cellulose synthesis requires chain initiation and elongation, and the two processes are separate. Cellulose synthase (CesA) initiates cellulose polymerization using a steroid primer, sitosterol-beta-glucoside, and UDP-glucose. It then utilises UDP-D-glucose precursors to elongate the growing cellulose chain. A cellulase may function to cleave the primer from the mature chain.
The United States investigated ricin for its military potential during World War I. At that time it was being considered for use either as a toxic dust or as a coating for bullets and shrapnel. The dust cloud concept could not be adequately developed, and the coated bullet/shrapnel concept would violate the Hague Convention of 1899 (adopted in U.S. law at 32 Stat. 1903), specifically Annex §2, Ch.1, Article 23, stating "... it is especially prohibited ... [t]o employ poison or poisoned arms". In 'Ricin and Abrin', Manashi Bagchi, Shirley Zafra-Stone, Francis C. Lau, and Debasis Bagchi wrote that during World War II the United States and Canada studied ricin in cluster bombs. Though there were plans for mass production and several field trials with different bomblet concepts, the end conclusion was that it was no more economical than using phosgene. This conclusion was based on comparison of the final weapons, rather than ricin's toxicity (LCt50 ~10 mg/min·m3). Ricin was given the military symbol W or later WA. Interest in it continued for a short period after World War II, but soon subsided when the US Army Chemical Corps began a program to weaponize sarin. The Soviet Union possessed weaponized ricin. The KGB developed weapons using ricin which were used outside the Soviet bloc, most famously in the Markov assassination.
In specialised cases the Van Leusen reaction can be used. Biocatalysts such as aliphatic aldoxime dehydratase are also effective. Aldoximes may also be dehydrated with cyanuric chloride, the Burgess reagent, or a combination of trifluoromethanesulfonic acid anhydride and triphenylphosphine, the latter being oxidized to triphenylphosphine oxide. Catalytic dehydrogenation is likewise possible, for example with iron(III) triflate, copper(II) acetate, mixed hydroxides of tin and tungsten, or a bimetallic palladium–manganese catalyst. Enzymatic dehydration of aldoximes using aldoxime dehydratases has also been achieved. These bacterial enzymes, including those from Pseudomonas chlororaphis, have been applied repeatedly in nitrile synthesis.
Sources: en.wikipedia.org
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.
Engaging two receptors recruits signaling pathways that only partly coincide. This can shift the magnitude of effects on insulin release, glucagon levels and appetite relative to selective agents. Whether the pairing delivers benefits beyond a simple sum of the two is still debated in the literature.
The proportional contribution of each receptor to observed clinical effects has not been fully separated. Long-term consequences of continuous dual stimulation are likewise unclear. Investigators continue to probe these points through laboratory and clinical work.
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.